A UK based bioscience company announced this week that it is close to a breakthrough in the treatment of one of the biggest cancer killers in dogs.
PetScreen, a pioneering British bioscience company, claims to have discovered an effective and innovative screening, detection and treatment programme for canine lymphoma, one of the most prolific cancers in dogs. It will be the first treatment of its kind, and should be commercially available from PetScreen’s Veterinary Cancer Programme, which was launched in the United States in January and in the UK in April at leading veterinary conference and congress events.
The lymphoma screen comes after extensive research by PetScreen in British and North American markets into canine cancer, and will be available through selected veterinary hospitals and primary practices in both markets. The screen is based on technology which enables malignancies to be detected earlier, when treatment has the best chance of success.
Inexpensive and convenient, the screen relies on a small blood serum sample and the system looks for characteristic patterns to detect lymphoma biomarkers from the blood ‘fingerprint’. A mature puppy would be sampled at twelve months, thereafter yearly, but in high risk breeds a six monthly screen is recommended. In addition, any dog which may have been treated for lymphoma should be screened bi-annually for recurrence.
Evidence suggests that 25% of all cancers in dogs is attributed to lymphoma. High risk breeds in both the UK and US for lymphoma cancer include golden and flat-coated retrievers, german shepherds, bull mastiffs and certain breeds of spaniels, including English and Irish water spaniels.
At risk breeds include boxers, Bernese mountain dogs and rottweilers.